Literature DB >> 17236490

The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia.

S Andrew Josephson1, Alexander M Papanastassiou, Mitchel S Berger, Nicholas M Barbaro, Michael W McDermott, Joan F Hilton, Bruce L Miller, Michael D Geschwind.   

Abstract

OBJECT: Obtaining brain biopsy specimens is often the diagnostic test of last resort for patients with unexplained neurological conditions, particularly those with a rapidly deteriorating neurological course. The goals of this analysis were to determine the diagnostic sensitivity of brain biopsy specimens in these types of patients and retrospectively identify features of these disorders that may have enabled an earlier diagnosis, which may prevent the need for diagnostic brain biopsy procedures in the future.
METHODS: The authors reviewed the case records of all brain biopsy procedures that had been performed at a single tertiary care institution between January 1993 and April 2002 in 171 patients. Patients with HIV or nonlymphomatous brain tumors were excluded from this analysis because the utility of brain biopsy specimens for these conditions has been determined front previous studies. A subgroup analysis of this cohort was performed in the 64 patients who had comprehensive medical records and a clinical syndrome involving a progressively deteriorating neurological condition of less than 1 year in duration. The overall sensitivity of brain biopsy procedures for diagnostic purposes in the cohort was 65% (111 of 171 patients). The two most common diagnoses in the subgroup with rapidly deteriorating neurological conditions were primary central nervous system (CNS) B-cell lymphoma in 20.3% (13 patients) and Creutzfeldt-Jakob disease in 15.6% (10 patients), followed by viral encephalitis in 14.1% (nine patients) and CNS vasculitis in 9.4% (six patients). Clinical symptoms and laboratory data were compared among the diagnostic groups.
CONCLUSIONS: These results will help guide the evaluation of patients with neurological conditions that are difficult to diagnose and will provide a foundation for further prospective studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236490     DOI: 10.3171/jns.2007.106.1.72

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  36 in total

1.  Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases.

Authors:  Sriram Venneti; John L Robinson; Subhojit Roy; Matthew T White; Jennifer Baccon; Sharon X Xie; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-09-30       Impact factor: 17.088

2.  A 54-year-old man with slowness of movement and confusion.

Authors:  Michael D Geschwind; Keith A Josephs; Joseph E Parisi; B Mark Keegan
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

3.  Infectious disease - developments in the field of Creutzfeldt-Jakob disease.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Rev Neurol Dis       Date:  2007

Review 4.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research.

Authors:  Kalyani Kansal; David J Irwin
Journal:  Psychiatr Clin North Am       Date:  2015-03-18

Review 6.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 7.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

8.  Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion.

Authors:  Albert J Schuette; Jason S Taub; Costas G Hadjipanayis; Jeffrey J Olson
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

9.  The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.

Authors:  M C Mabray; R F Barajas; J E Villanueva-Meyer; C A Zhang; F E Valles; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

Review 10.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.